ICD-10-GM: F20, F25, F30-34, F40-42
Conditions
Interventions
Group 1: Intervention Group
Pharmaceutical care for 12 months in an intensive form
-Regular contact initiated by the community pharmacy
-In-person appointment: Month 0
-Digital contact (via app or t
Sponsors
Johannes Gutenberg-Universität Mainz, Institut für Pharmazeutische und Biomedizinische Wissenschaften
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: -Sufficient knowledge of the German language -Psychiatric diagnosis according to ICD-10: F20, F25, F30-34, F40-42 -Currently prescribed at least one disorder-specific medication -Patients insured with any statutory or private health insurance
Exclusion criteria
Exclusion criteria: -Psychiatric diagnosis according to ICD-10, including: F00–F09 (organic, including symptomatic, mental disorders), F00-09, F10-19, F21, F22, F23, F24, F28, F29, F38, F39, F43-48, F50-F59, F60-69, F70-79, F80-89, F90-98, F99 -No confirmed ICD-10 diagnosis code available from the treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of adherence using the 15-STARS questionnaire (month 0, 6, 12) | — |
Secondary
| Measure | Time frame |
|---|---|
| -Attitude toward psychiatric medication assessed using the Drug Attitude Inventory (DAI) (month 0, 6, 12) -Identification and evaluation of adverse drug reactions using the UKU Side Effect Rating Scale (Udvalg for Kliniske Undersøgelser, Scandinavian College of Neuropsychopharmacology) (month 0, 6, 12) -Number and classification of drug-related problems using PCNE Classification V9.1 (month 0, 6, 12) -Assessment of subjective psychological distress using the Brief Symptom Checklist (BSCL) (month 0, 6, 12) -Evaluation of quality of life using the SF-12 Health Survey (month 0, 6, 12) | — |
Countries
Germany
Contacts
Public ContactKristina Friedland
Institut für Pharmazeutische und Biomedizinische Wissenschaften
Outcome results
None listed